Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
AVBP Stock Chart & Stats
$25.25
$0.14(0.52%)
At close: 4:00 PM EST
$25.25
$0.14(0.52%)
Day’s Range― - ―
52-Week Range$15.47 - $27.22
Previous CloseN/A
Volume49.09K
Average Volume (3M)461.60K
Market Cap
$1.04B
Enterprise Value$921.70M
Total Cash (Recent Filing)$312.82M
Total Debt (Recent Filing)$14.00K
Price to Earnings (P/E)―
Beta0.95
Next Earnings
May 13, 2026EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding41,281,360
10 Day Avg. Volume402,216
30 Day Avg. Volume461,602
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.92
Forecast
1Y Price Target
$43.38Price Target Upside71.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.94
Revenue Forecast (FY)$125.00K
Bulls Say, Bears Say
Bulls Say
Commercial Leadership And Market PreparationAppointment of a Chief Commercial Officer with extensive U.S. and global commercialization experience signals readiness to scale launch efforts and could improve commercial execution for firmonertinib.
Pivotal Phase 3 ReadoutA pivotal Phase 3 topline readout for firmonertinib in first-line EGFR exon 20 insertion lung cancer could drive significant stock appreciation if the oral drug demonstrates clear benefit versus standard therapies.
Regulatory Progress And ApprovalsRegulatory clearance to advance ARR-217 into early-stage clinical study in China, combined with firmonertinib's existing approval in China and Breakthrough Therapy Designation in the U.S., supports an accelerated development and commercial pathway.
Bears Say
Binary Clinical Outcome RiskInvestor treatment of the upcoming pivotal trial as a binary event creates heightened downside risk from a negative readout, which could trigger a sharp stock decline.
Competitive Pressure In First-line SettingDirect competition from established therapies and rival oral inhibitors, and the use of competing drugs with chemotherapy, could limit firmonertinib's market uptake even with positive efficacy.
Financial Runway And Dilution RiskHigh cash burn and a limited cash runway raise the likelihood of dilutive financing if clinical progress stalls, increasing pressure on the share price.
ArriVent BioPharma, Inc. News
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $15.47 and its highest was $27.22 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $1.04B.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is May 13, 2026 which is in 67 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on Mar 05, 2026. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.846 by $0.006.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -0.89.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 41,281,360 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.846. Following the earnings report the stock price went down -7.208%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ArriVent BioPharma, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.38 (71.78% Upside)
$43.38 (71.78% Upside)
Blogger Sentiment
Bullish
AVBP Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 151.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 18.5%
Last 30 Days ▼ 18.5%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 13%
Bearish news 13%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.37%
12-Months-Change
Fundamentals
Return on Equity
-51.98%
Trailing 12-Months
Asset Growth
11.56%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
AVBP Stock 12 Month Forecast
Average Price Target
$43.38
▲(71.78% Upside)
Technical Analysis
uniQure
―
Iovance Biotherapeutics
―
Relay Therapeutics
―
Inventiva
―
Taysha Gene Therapies
―
Ownership Overview
Currently, No data available
---